Lanzhou University First Affiliated Hospital, Lanzhou, 730000, China.
Dig Dis Sci. 2018 Feb;63(2):321-328. doi: 10.1007/s10620-017-4899-x. Epub 2018 Jan 5.
To compare the therapeutic effects of I versus non-I combined with transcatheter arterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) with obstructive jaundice.
A retrospective analysis was conducted using the records of 54 consecutive patients who were initially diagnosed with HCC with obstructive jaundice between May 2009 and July 2016. Twenty-one cases (group A) were treated with percutaneous transhepatic biliary drainage (PTBD) followed by I radioactive seed strip implantation through the PTBD tube. After the total serum bilirubin level was reduced to normal and the liver function recovered to Child-Pugh class A or early B, TACE was conducted. In 33 cases (group B) PTBD was performed in combination with TACE without applying the I radioactive seeds. The duration of biliary patency and survival were analyzed.
The technical success rate in both groups was 100%. The median biliary patency time was 6.000 ± 0.315 months (95% CI 5.382-6.618 months) in group A and 4.000 ± 0.572 months (95% CI 2.879-5.121 months) in group B; the two groups were significantly different (P = 0.001). The median survival was 11.000 ± 0.864 months (95% CI 9.306-12.694 months) in group A and 9.000 ± 0.528 months (95% CI 7.965-10.035 months) in group B; the two groups were significantly different (P = 0.022).
The combination of 125I with TACE was more effective than TACE without the radioactive seeds for treating patients with unresectable HCC with obstructive jaundice. Future prospective trials with larger samples will be required to validate these results.
比较 I 联合与不联合经导管肝动脉化疗栓塞(TACE)治疗伴梗阻性黄疸的不可切除肝细胞癌(HCC)的疗效。
回顾性分析 2009 年 5 月至 2016 年 7 月期间连续收治的 54 例伴梗阻性黄疸的 HCC 患者的临床资料。21 例(A 组)患者接受经皮经肝胆道引流(PTBD),并通过 PTBD 管植入 I 放射性粒子条。待总胆红素水平降至正常,肝功能恢复至 Child-Pugh A 级或早期 B 级后,行 TACE。33 例(B 组)患者行 PTBD 联合 TACE 治疗,不应用 I 放射性粒子。分析两组患者的胆道通畅时间和生存时间。
两组患者的技术成功率均为 100%。A 组的中位胆道通畅时间为 6.000±0.315 个月(95%CI:5.382-6.618 个月),B 组为 4.000±0.572 个月(95%CI:2.879-5.121 个月),两组比较差异有统计学意义(P=0.001)。A 组的中位生存时间为 11.000±0.864 个月(95%CI:9.306-12.694 个月),B 组为 9.000±0.528 个月(95%CI:7.965-10.035 个月),两组比较差异有统计学意义(P=0.022)。
125I 联合 TACE 治疗伴梗阻性黄疸的不可切除 HCC 患者较单纯 TACE 治疗更有效,需进一步开展大样本前瞻性研究以验证上述结果。